PPARA and metabolic dysfunction-associated steatohepatitis: Although still much has to be realized [90], the interconnection of in vitro surrogate organs such as liver, pancreas, and adipose tissue, merged with data of humanized animal models, could enable more reliable PPAR-targeted anti-NASH drug testing and thus improve clinical outcomes.